PDCD1LG2 and cancer: Multivariable adjustment for standard clinicopathological risk factors using a parsimonious model fitted to this subgroup of 197 chemotherapy-treated patients (Table 3) confirmed a strong effect of high cancer cell PD-L2 on PFS in patients treated with adjuvant chemotherapy (HR, 3.4; 95% CI, 1.8 to 6.2; P < .001).